NASDAQ:JUNS

Jupiter Neurosciences (JUNS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
JUNS stock logo

About Jupiter Neurosciences Stock (NASDAQ:JUNS)

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

JUNS Stock News Headlines

Why We Lie, And The Neuroscience Behind It
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
FAU opens $45M neuroscience building (Photos)
Jupiter Neurosciences Inc (JUNS)
See More Headlines
Receive JUNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jupiter Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:JUNS
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Christer Rosen (Age 69)
    Co-Founder, CEO & Chairman
    Comp: $632.23k
  • Ms. Alison D. Silva MA (Age 43)
    MS, Pres, Chief Bus. Officer & Director
  • Dr. Claes Wahlestedt M.D. (Age 63)
    Ph.D., Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer
  • Dr. Marshall Hayward Ph.D. (Age 67)
    Co-Founder, Chief Scientific Officer & Director
    Comp: $441.75k
  • Ms. Dana Eschenburg Perez CPA (Age 45)
    CFO, Sec. & Treasurer
    Comp: $360.87k
  • Dr. Shaun P. Brothers Ph.D. (Age 43)
    Co-Founder, Consulting Head of Scientific Research & Member of Scientific Advisory Board
  • Mr. Alexander Rosen (Age 31)
    Co-Founder & Chief Admin. Officer

JUNS Stock Analysis - Frequently Asked Questions

When did Jupiter Neurosciences IPO?

Jupiter Neurosciences (JUNS) raised $15 million in an IPO on Wednesday, September 21st 2022. The company issued 2,500,000 shares at $5.00-$7.00 per share. Spartan Capital acted as the underwriter for the IPO.

This page (NASDAQ:JUNS) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners